Hugel
Hugel Inc is a South Korean multinational biopharmaceutical and medical aesthetics company specializing in the research, development, and manufacturing of botulinum toxin products, hyaluronic acid dermal fillers, and therapeutic pharmaceutical formulations. The company produces high-purity botulinum toxin type A products (marketed under brands like Botulax) and medical aesthetic solutions supplied to dermatologists, plastic surgeons, and medical clinics across South Korea and international export markets. Its core business operations encompass biopharmaceutical research, sterile toxin manufacturing, aesthetic product formulation, and global wholesale distribution. Revenue is derived directly from the global wholesale sale of medical aesthetic products and pharmaceuticals to healthcare distributors. Hugel holds a leading market position in botulinum toxin manufacturing and aesthetic medicine in South Korea. The company is headquartered in Chuncheon, South Korea, and its shares trade on the Korea Exchange.
7 of the funds FundTelligence covers report a position in Hugel.
- Legal name
- HUGEL INC
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 7
Funds holding Hugel
- Schroder ISF Global Emerging Markets Smaller Companies — Schroders · 1.88 % (full portfolio disclosed, June 2026)
- Templeton Asian Smaller Companies Fund — Franklin Templeton · 1.57 % (full portfolio disclosed, September 2026)
- Templeton Emerging Markets Smaller Companies Fund — Franklin Templeton · 1.41 % (full portfolio disclosed, September 2026)
- JPM Emerging Markets Small Cap Fund — JPM · 0.99 % (full portfolio disclosed, June 2026)
- JPM Korea Equity Fund — JPM · 0.93 % (full portfolio disclosed, June 2026)
- JPM Asia Growth Fund — JPM · 0.52 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)